Total Payments
$13,213
2024 Payments
$2,901
Companies
63
Transactions
294
Medicare Patients
20,671
Medicare Billing
$7.0M
Payment Breakdown by Category
Food & Beverage$12,734 (96.4%)
Education$479.57 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,734 | 284 | 96.4% |
| Education | $479.57 | 10 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,755 | 29 | $0 (2024) |
| Janssen Biotech, Inc. | $905.17 | 19 | $0 (2024) |
| Amgen Inc. | $885.36 | 10 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $614.55 | 14 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $572.67 | 13 | $0 (2024) |
| Genentech USA, Inc. | $545.54 | 9 | $0 (2023) |
| ABBVIE INC. | $458.53 | 13 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $418.73 | 4 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $396.04 | 19 | $0 (2024) |
| PFIZER INC. | $394.72 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,901 | 100 | AstraZeneca Pharmaceuticals LP ($423.52) |
| 2023 | $2,100 | 52 | AstraZeneca Pharmaceuticals LP ($245.49) |
| 2022 | $468.88 | 13 | Incyte Corporation ($110.27) |
| 2021 | $80.63 | 5 | Incyte Corporation ($21.49) |
| 2020 | $262.89 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($127.29) |
| 2019 | $2,522 | 42 | AstraZeneca Pharmaceuticals LP ($557.07) |
| 2018 | $2,950 | 42 | Novartis Pharmaceuticals Corporation ($389.03) |
| 2017 | $1,928 | 35 | Amgen Inc. ($336.71) |
All Payment Transactions
294 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Oncology | ||||||
| 12/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $39.35 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: Oncology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $11.17 | General |
| 11/20/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Oncology | ||||||
| 11/16/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Oncology | ||||||
| 11/15/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Education | In-kind items and services | $95.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $29.79 | General |
| Category: NONE | ||||||
| 10/29/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Oncology | ||||||
| 10/24/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $11.25 | General |
| 10/23/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $114.14 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $21.92 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $85.34 | General |
| 10/16/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Oncology | ||||||
| 10/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $6.68 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 81 | 5,128 | 132,143 | $9.0M | $1.7M |
| 2022 | 83 | 5,104 | 131,449 | $9.1M | $1.8M |
| 2021 | 83 | 5,109 | 147,215 | $9.7M | $2.0M |
| 2020 | 79 | 5,330 | 112,166 | $7.6M | $1.6M |
Total Patients
20,671
Total Services
522,973
Medicare Billing
$7.0M
Procedure Codes
326
All Medicare Procedures & Services
326 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 32 | 12,800 | $1.7M | $551,690 | 31.7% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 20 | 13,880 | $1.1M | $327,480 | 31.0% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 13 | 5,940 | $757,080 | $218,607 | 28.9% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 25 | 3,260 | $760,830 | $108,844 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 449 | 878 | $323,104 | $78,826 | 24.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 237 | 455 | $321,685 | $43,619 | 13.6% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 13 | 1,590 | $246,450 | $37,928 | 15.4% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 78 | 105 | $180,810 | $36,698 | 20.3% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 49 | 123 | $339,726 | $33,355 | 9.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,800 | $117,240 | $32,916 | 28.1% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 19 | 324 | $436,752 | $29,648 | 6.8% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 12 | 1,179 | $213,399 | $27,721 | 13.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 22 | 8,935 | $178,700 | $20,969 | 11.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 12 | 14 | $67,228 | $15,438 | 23.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 444 | 1,100 | $70,400 | $11,325 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 69 | 69 | $48,921 | $10,590 | 21.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 150 | 216 | $67,608 | $9,962 | 14.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 451 | 1,167 | $23,340 | $9,755 | 41.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 35 | 24,480 | $122,400 | $9,374 | 7.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 439 | 1,068 | $38,448 | $8,096 | 21.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 206 | 692 | $74,736 | $7,961 | 10.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 89 | 149 | $51,256 | $7,232 | 14.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 38 | 42 | $44,814 | $6,541 | 14.6% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 32 | 53 | $26,500 | $6,440 | 24.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 33 | 112 | $23,632 | $5,996 | 25.4% |
About Jingdong Su
Jingdong Su is a Internal Medicine healthcare provider based in Tyler, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1669607479.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jingdong Su has received a total of $13,213 in payments from pharmaceutical and medical device companies, with $2,901 received in 2024. These payments were reported across 294 transactions from 63 companies. The most common payment nature is "Food and Beverage" ($12,734).
As a Medicare-enrolled provider, Su has provided services to 20,671 Medicare beneficiaries, totaling 522,973 services with total Medicare billing of $7.0M. Data is available for 4 years (2020–2023), covering 326 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Student in an Organized Health Care Education/Training Program, Hematology & Oncology
- Location Tyler, TX
- Active Since 05/22/2009
- Last Updated 07/08/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1669607479
Products in Payments
- DARZALEX (Biological) $802.82
- KEYTRUDA (Biological) $614.55
- IMBRUVICA (Drug) $479.59
- LYNPARZA (Drug) $455.97
- ZEJULA (Drug) $370.33
- Cabometyx (Drug) $369.64
- IMFINZI (Biological) $310.31
- TAGRISSO (Drug) $282.10
- TECENTRIQ (Biological) $254.17
- NINLARO (Drug) $251.71
- XT CDX (Device) $251.27
- Nerlynx (Drug) $245.99
- Kyprolis (Biological) $241.87
- XTANDI (Drug) $233.70
- CALQUENCE (Drug) $227.15
- MONJUVI (Drug) $215.02
- Kyprolis (Drug) $212.94
- IMFINZI (Drug) $211.03
- Orserdu (Drug) $181.18
- ERBITUX (Drug) $180.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tyler
Dr. Pamela Mcshane, M.d, M.D
Internal Medicine — Payments: $243,956
Internal Medicine $243,956
Thomas Buzbee, M.d, M.D
Internal Medicine — Payments: $123,613
Internal Medicine $123,613
Preetham Muskula, Md, MD
Internal Medicine — Payments: $89,345
Internal Medicine $89,345
Dr. Julie Philley, Md, MD
Internal Medicine — Payments: $68,306
Internal Medicine $68,306
Alexandre Petrakian, Md, MD
Internal Medicine — Payments: $37,685
Internal Medicine $37,685
Kai Xia, Md, MD
Internal Medicine — Payments: $24,476
Internal Medicine $24,476